Today, there’s another innovative choice to treat
advanced melanoma, a type of skin cancer.

Opdualag®: a one-of-a-kind treatment that joins 2 immunotherapies into a single medicine.

Opdualag is a dual immunotherapy and the first FDA-approved treatment of its kind that may help fight advanced melanoma, a type of skin cancer.

How does Opdualag work with my immune system?

Opdualag is an immunotherapy treatment that works with some of the T cells of your immune system.

Learning more about this treatment can help you have better conversations with your healthcare team when discussing advanced melanoma skin cancer treatment decisions.

Opdualag may help activate your immune system

by combining 2 different immunotherapies into 1 medicine

T cells attacking a cancer cell.
T cells attacking a cancer cell.

Your immune system has T cells that attack cancer cells.

Tired T cell.

But T cells can get tired.

Opdualag® combines Nivolumab and Relatimab to activate tired T cells.

Two immunotherapies connect to some T cells and work in sync to activate them.

Activated T cell.

Activated T cells can help get your immune system ready to attack cancer.

This is a general example of how Opdualag works. Each patient is different and clinical results may vary.

Opdualag can cause your T cells to attack healthy cells contained within organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death, and may happen anytime during treatment or even after treatment has ended. You may have more than one of these problems at the same time. Your doctor will check for these problems during treatment.

Please see Important Safety Information.

Select Important Facts

Opdualag can cause problems that can sometimes become serious or life-threatening and can lead to death. Serious side effects may include:

  • Lung problems
  • Intestinal problems
  • Liver problems
  • Hormone gland problems
  • Kidney problems
  • Skin problems
  • Heart problems
  • Problems in other organs and tissues
  • Severe infusion reactions
  • Complications of bone marrow (stem cell) transplant that uses donor stem cells (allogeneic)

NEXT: Efficacy



© 2025 Bristol-Myers Squibb Company.
Opdualag®, Access Support®, Opdualag™ with You, and the related logos are trademarks of Bristol-Myers Squibb Company.

This site is intended for U.S. residents 18 years of age or older.

1425-US-2500035  09/25